8-K Announcements
6Material company update
May 5, 2026·SEC
Material company update
Feb 23, 2026·SEC
Material company update
Jan 12, 2026·SEC
Myriad Genetics, Inc.(MYGN)Earnings, Financials & Key Ratios
MYGN•NASDAQ
$4.11
$384M mkt cap·Price updated May 6, 2026
AboutMyriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, a RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, a RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. In addition, it provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, ADHD, and other mental health conditions. Myriad Genetics, Inc. has a strategic collaboration with Illumina, Inc. and Intermountain Precision Genomics for an offering of germline and somatic tumor testing services. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.Show more
- Revenue$825M-1.6%
- EBITDA-$14M+77.4%
- Net Income-$366M-187.4%
- EPS (Diluted)-3.96-180.9%
- Gross Margin69.93%
- EBITDA Margin-1.71%+77.0%
- Operating Margin-8.22%+44.2%
- Net Margin-44.38%-192.0%
- ROE-68.45%-299.1%
- ROIC-8.71%+27.5%
- Debt/Equity0.57+184.9%
- Interest Coverage-36.63+15.0%
MYGN Key Insights
Myriad Genetics, Inc. (MYGN) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Trading at only 1.0x book value
- ✓Efficient asset utilization: 1.2x turnover
✗Weaknesses
- ✗Profits declining 10.3% over 5 years
- ✗Negative free cash flow
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
MYGN Price & Volume
Myriad Genetics, Inc. (MYGN) stock price & volume — 10-year historical chart
Loading chart...
MYGN Growth Metrics
Myriad Genetics, Inc. (MYGN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years0.9%
5 Years8.16%
3 Years6.72%
TTM-0.28%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-294.38%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-283.97%
Return on Capital
10 Years-8.96%
5 Years-15.34%
3 Years-15.95%
Last Year-9.44%
MYGN Recent Earnings
Myriad Genetics, Inc. (MYGN) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 6/12 qtrs (50%)
Q2 2026Latest
May 5, 2026EPS
$0.09
Est $0.06
-50.0%
Revenue
$200M
Est $202M
-1.0%
Q1 2026
Feb 23, 2026EPS
$0.04
Est $0.02
+300.0%
Revenue
$210M
Est $207M
+1.1%
Q4 2025
Nov 3, 2025EPS
$0.13
Est $0.01
-1200.0%
Revenue
$206M
Est $207M
-0.6%
Q3 2025
Aug 5, 2025EPS
$0.05
Est $0.01
+600.0%
Revenue
$213M
Est $205M
+3.8%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $0.09vs $0.06-50.0% | $200Mvs $202M-1.0% |
| Q1 2026 | Feb 23, 2026 | $0.04vs $0.02+300.0% | $210Mvs $207M+1.1% |
| Q4 2025 | Nov 3, 2025 | $0.13vs $0.01-1200.0% | $206Mvs $207M-0.6% |
| Q3 2025 | Aug 5, 2025 | $0.05vs $0.01+600.0% | $213Mvs $205M+3.8% |
Based on last 12 quarters of dataView full earnings history →
MYGN Peer Comparison
Myriad Genetics, Inc. (MYGN) competitors in Molecular and Genetic Diagnostics — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 NTRA | 29.58B | 215.09 | -140.58 | 56.75% | -14.61% | -24.69% | 0.16 | |
 EXAS | 20.02B | 104.91 | -95.37 | 17.69% | -6.4% | -8.66% | 1.05 | |
 VCYT | 3.29B | 41.19 | 50.23 | 16.01% | 16.25% | 6.86% | 0.03 | |
 CDNA | 1.08B | 20.94 | -52.35 | 13.79% | -1.98% | -2.61% | 0.06 | |
 ILMN | 21.66B | 142.58 | 26.16 | -0.78% | 19.43% | 32.84% | 0.94 | |
 PACB | 516.17M | 1.71 | -1.60 | -23.19% | -325.8% | -13.95% | 1.33 | |
 GH | 11.53B | 92.25 | -27.79 | 32.88% | -44.18% | |||
 FLGT | 443.83M | 14.92 | -7.57 | 13.83% | -18.75% | -5.42% | 0.00 |
Compare MYGN vs Peers
Myriad Genetics, Inc. (MYGN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
MYGN Income Statement
Myriad Genetics, Inc. (MYGN) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Jun'18 | Jun'19 | Jun'20 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 772.6M | 851.1M | 638.6M | 557M | 690.6M | 678.4M | 753.2M | 837.6M | 824.5M | 829M |
| Revenue Growth % | 0.16% | 10.16% | -24.97% | -12.78% | 23.99% | -1.77% | 11.03% | 11.21% | -1.56% | -0.28% |
| Cost of Goods Sold | 177.2M | 201M | 186.1M | 178.2M | 197.6M | 202M | 236.2M | 252.2M | 247.9M | 249M |
| COGS % of Revenue | 22.94% | 23.62% | 29.14% | 31.99% | 28.61% | 29.78% | 31.36% | 30.11% | 30.07% | - |
| Gross Profit | 595.4M▲ 0% | 650.1M▲ 9.2% | 452.5M▼ 30.4% | 378.8M▼ 16.3% | 493M▲ 30.1% | 476.4M▼ 3.4% | 517M▲ 8.5% | 585.4M▲ 13.2% | 576.6M▼ 1.5% | 580M▲ 0% |
| Gross Margin % | 77.06% | 76.38% | 70.86% | 68.01% | 71.39% | 70.22% | 68.64% | 69.89% | 69.93% | 69.96% |
| Gross Profit Growth % | -0.8% | 9.19% | -30.4% | -16.29% | 30.15% | -3.37% | 8.52% | 13.23% | -1.5% | - |
| Operating Expenses | 537.9M | 642.5M | 684.2M | 653.3M | 683.5M | 617M | 774.4M | 708.9M | 644.4M | 963.5M |
| OpEx % of Revenue | 69.62% | 75.49% | 107.14% | 117.29% | 98.97% | 90.95% | 102.81% | 84.63% | 78.16% | - |
| Selling, General & Admin | 467.1M | 556.6M | 507.3M | 500.7M | 537.8M | 514.7M | 572.9M | 560M | 537.6M | 537.7M |
| SG&A % of Revenue | 60.46% | 65.4% | 79.44% | 89.89% | 77.87% | 75.87% | 76.06% | 66.86% | 65.2% | - |
| Research & Development | 70.8M | 85.9M | 77.2M | 80.9M | 81.9M | 85.4M | 88.7M | 113.4M | 106.8M | 106.4M |
| R&D % of Revenue | 9.16% | 10.09% | 12.09% | 14.52% | 11.86% | 12.59% | 11.78% | 13.54% | 12.95% | - |
| Other Operating Expenses | -400K | 0 | 99.7M | 0 | 63.8M | 16.9M | 112.8M | 35.5M | 0 | 2M |
| Operating Income | 118.7M▲ 0% | 7.6M▼ 93.6% | -231.7M▼ 3148.7% | -194.8M▲ 15.9% | -190.5M▲ 2.2% | -140.6M▲ 26.2% | -257.4M▼ 83.1% | -123.5M▲ 52.0% | -67.8M▲ 45.1% | -383.5M▲ 0% |
| Operating Margin % | 15.36% | 0.89% | -36.28% | -34.97% | -27.58% | -20.73% | -34.17% | -14.74% | -8.22% | -46.26% |
| Operating Income Growth % | 140.28% | -93.6% | -3148.68% | 15.93% | 2.21% | 26.19% | -83.07% | 52.02% | 45.1% | - |
| EBITDA | 173.1M | 80.6M | -159.7M | -123.4M | -127.7M | -87.9M | -195.5M | -62.3M | -14.1M | -344.2M |
| EBITDA Margin % | 22.4% | 9.47% | -25.01% | -22.15% | -18.49% | -12.96% | -25.96% | -7.44% | -1.71% | -41.52% |
| EBITDA Growth % | 77.18% | -53.44% | -298.14% | 22.73% | -3.48% | 31.17% | -122.41% | 68.13% | 77.37% | -432.82% |
| D&A (Non-Cash Add-back) | 54.4M | 73M | 72M | 71.4M | 62.8M | 52.7M | 61.9M | 61.2M | 53.7M | 39.3M |
| EBIT | 0 | 12M | -212.5M | -194.8M | -50.5M | -137.4M | -259.3M | -120.7M | -384.6M | -356M |
| Net Interest Income | -1.4M | -8.8M | -7.8M | 9.2M | -5.9M | -600K | -400K | -1.1M | -8.7M | -8.2M |
| Interest Income | 1.8M | 3.2M | 3M | 9.2M | 700K | 2.6M | 2.5M | 1.7M | 1.8M | 2.2M |
| Interest Expense | 3.2M | 12M | 10.8M | 0 | 6.6M | 3.2M | 2.9M | 2.8M | 10.5M | 5.6M |
| Other Income/Expense | 60.8M | -7.6M | 8.4M | -88.9M | 133.4M | 0 | -4.8M | 0 | -327.3M | -16.3M |
| Pretax Income | 116.9M▲ 0% | 0▼ 100.0% | -223.3M▲ 0% | -283.7M▼ 27.0% | -57.1M▲ 79.9% | -140.6M▼ 146.2% | -262.2M▼ 86.5% | -123.5M▲ 52.9% | -395.1M▼ 219.9% | -399.8M▲ 0% |
| Pretax Margin % | 15.13% | - | -34.97% | -50.93% | -8.27% | -20.73% | -34.81% | -14.74% | -47.92% | -48.23% |
| Income Tax | -13.9M | -4.4M | -23.7M | 59.9M | -29.9M | -28.6M | 1.1M | 3.8M | -29.2M | 100K |
| Effective Tax Rate % | -11.89% | - | 10.61% | -21.11% | 52.36% | 20.34% | -0.42% | -3.08% | 7.39% | -0.03% |
| Net Income | 131M▲ 0% | 4.6M▼ 96.5% | -199.5M▼ 4437.0% | -223.7M▼ 12.1% | -27.2M▲ 87.8% | -112M▼ 311.8% | -263.3M▼ 135.1% | -127.3M▲ 51.7% | -365.9M▼ 187.4% | -399.9M▲ 0% |
| Net Margin % | 16.96% | 0.54% | -31.24% | -40.16% | -3.94% | -16.51% | -34.96% | -15.2% | -44.38% | -48.24% |
| Net Income Growth % | 500.92% | -96.49% | -4436.96% | -12.13% | 87.84% | -311.76% | -135.09% | 51.65% | -187.43% | -294.38% |
| Net Income (Continuing) | - | 4.4M | -199.6M | - | -27.2M | -112M | -263.3M | -127.3M | -365.9M | -399.9M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | 1.82▲ 0% | 0.06▼ 96.7% | -2.69▼ 4538.2% | -2.99▼ 11.4% | -0.35▲ 88.3% | -1.39▼ 297.1% | -3.18▼ 128.8% | -1.41▲ 55.7% | -3.96▼ 180.9% | -4.27▲ 0% |
| EPS Growth % | 468.75% | -96.67% | -4536.19% | -11.36% | 88.29% | -297.14% | -128.78% | 55.66% | -180.85% | -283.97% |
| EPS (Basic) | 1.89 | 0.06 | -2.69 | -2.99 | -0.35 | -1.39 | -3.18 | -1.41 | -3.96 | - |
| Diluted Shares Outstanding | 72M | 76M | 74.3M | 74.78M | 78M | 80.6M | 82.8M | 90.6M | 93.3M | 93.7M |
| Basic Shares Outstanding | 69.4M | 73.5M | 74.3M | 74.7M | 77.71M | 80.58M | 82.8M | 90.6M | 93.3M | 93.7M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
MYGN Balance Sheet
Myriad Genetics, Inc. (MYGN) balance sheet — assets, liabilities & shareholders' equity
| Line item | Jun'18 | Jun'19 | Jun'20 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 326.4M | 348.6M | 348.6M | 389.4M | 484.8M | 274.6M | 313.6M | 298M | 332.6M | 312.8M |
| Cash & Short-Term Investments | 180.6M | 136.9M | 136.9M | 150.7M | 339.8M | 114.9M | 140.9M | 102.4M | 149.6M | 124.4M |
| Cash Only | 110.9M | 93.2M | 93.2M | 117M | 258.4M | 56.9M | 132.1M | 102.4M | 149.6M | 124.4M |
| Short-Term Investments | 69.7M | 43.7M | 43.7M | 33.7M | 81.4M | 58M | 8.8M | 0 | 0 | 0 |
| Accounts Receivable | 102.1M | 138.6M | 138.6M | 89.5M | 91.3M | 101.6M | 114.3M | 121.2M | 115.3M | 123.8M |
| Days Sales Outstanding | 48.24 | 59.44 | 79.22 | 58.65 | 48.25 | 54.66 | 55.39 | 52.82 | 51.04 | 54.39 |
| Inventory | 34.3M | 31.4M | 31.4M | 27.1M | 15.3M | 20.1M | 22M | 27.5M | 30.6M | 27.9M |
| Days Inventory Outstanding | 70.65 | 57.02 | 61.59 | 55.51 | 28.26 | 36.32 | 34 | 39.8 | 45.05 | 43.54 |
| Other Current Assets | 9.4M | 46.4M | 41.7M | 0 | 38.4M | 20.4M | 19.4M | 30.5M | 37.1M | 36.7M |
| Total Non-Current Assets | 847.7M | 1.21B | 1.21B | 1.03B | 835.9M | 924.1M | 832.9M | 729.6M | 374M | 360.9M |
| Property, Plant & Equipment | 43.2M | 57.3M | 57.3M | 100.4M | 125.3M | 187.3M | 180.6M | 172.4M | 163.4M | 162.5M |
| Fixed Asset Turnover | 17.88x | 14.85x | 11.14x | 5.55x | 5.51x | 3.62x | 4.17x | 4.86x | 5.05x | 5.09x |
| Goodwill | 318.6M | 417.2M | 417.2M | 329.2M | 239.2M | 286.8M | 287.4M | 286.3M | 51.6M | 47.1M |
| Intangible Assets | 455.2M | 684.7M | 684.7M | 578.8M | 404.1M | 379.7M | 349.5M | 262.4M | 153.4M | 145.7M |
| Long-Term Investments | 30.7M | 54.9M | 54.9M | 21M | 59M | 54.8M | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | -1.21B | 0 | 0 | 8.3M | 15.5M | 15.4M | 8.5M | 5.6M | 24.9M |
| Total Assets | 1.17B▲ 0% | 1.56B▲ 33.1% | 1.56B▲ 0.0% | 1.42B▼ 9.2% | 1.32B▼ 6.9% | 1.2B▼ 9.2% | 1.15B▼ 4.4% | 1.03B▼ 10.4% | 706.6M▼ 31.2% | 673.7M▲ 0% |
| Asset Turnover | 0.66x | 0.54x | 0.41x | 0.39x | 0.52x | 0.57x | 0.66x | 0.82x | 1.17x | 1.19x |
| Asset Growth % | -4.11% | 33.1% | 0% | -9.21% | -6.91% | -9.24% | -4.35% | -10.37% | -31.24% | -134.52% |
| Total Current Liabilities | 102.2M | 117.8M | 117.8M | 145.9M | 204.3M | 137.2M | 155.9M | 164.1M | 133.8M | 130.2M |
| Accounts Payable | 26M | 33.3M | 33.3M | 20.5M | 29.6M | 28.8M | 25.8M | 32.3M | 30M | 32.6M |
| Days Payables Outstanding | 53.56 | 60.47 | 65.31 | 41.99 | 54.68 | 52.04 | 39.87 | 46.75 | 44.17 | 45.92 |
| Short-Term Debt | 68.3M | 78.9M | 78.9M | 0 | 13M | 14.1M | 0 | 0 | 6.9M | 7.1M |
| Deferred Revenue (Current) | 2.6M | 2.2M | 2.2M | 0 | 5.2M | 600K | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 5.3M | 82.3M | -29.9M | 49.7M | 126.9M | 64.9M | 38.2M | 64.9M | 96.9M | 90.5M |
| Current Ratio | 3.19x | 2.96x | 2.96x | 2.67x | 2.37x | 2.00x | 2.01x | 1.82x | 2.49x | 2.49x |
| Quick Ratio | 2.86x | 2.69x | 2.69x | 2.48x | 2.30x | 1.85x | 1.87x | 1.65x | 2.26x | 2.26x |
| Cash Conversion Cycle | 65.33 | 55.99 | 75.49 | 72.17 | 21.84 | 38.94 | 49.52 | 45.87 | 51.93 | 52 |
| Total Non-Current Liabilities | 107M | 356M | 356M | 391.9M | 148.6M | 175.7M | 207.4M | 162.4M | 204.8M | 206.1M |
| Long-Term Debt | 9.3M | 233.5M | 233.5M | 224.8M | 79.3M | 130.9M | 38.5M | 39.6M | 202.9M | 204.4M |
| Capital Lease Obligations | 0 | 0 | 0 | 50.6M | 0 | 0 | 97.4M | 87.9M | 0 | 171.1M |
| Deferred Tax Liabilities | 57.3M | 82.6M | 82.6M | 0 | 35.8M | 3.5M | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 40.4M | 39.9M | 39.9M | 116.5M | 33.5M | 41.3M | 71.5M | 34.9M | 1.9M | 9.6M |
| Total Liabilities | 209.2M | 473.8M | 473.8M | 537.8M | 352.9M | 312.9M | 363.3M | 326.5M | 338.6M | 336.3M |
| Total Debt | 9.3M | 233.5M | 233.5M | 289M | 92.3M | 145M | 152.1M | 140.3M | 209.8M | 211.5M |
| Net Debt | -101.6M | 140.3M | 140.3M | 172M | -166.1M | 88.1M | 20M | 37.9M | 60.2M | 87.1M |
| Debt / Equity | 0.01x | 0.21x | 0.21x | 0.33x | 0.10x | 0.16x | 0.19x | 0.20x | 0.57x | 0.57x |
| Debt / EBITDA | 0.05x | 2.90x | - | - | - | - | - | - | - | -0.61x |
| Net Debt / EBITDA | -0.59x | 1.74x | - | - | - | - | - | - | - | -0.25x |
| Interest Coverage | 37.09x | 1.00x | -19.68x | - | -7.65x | -42.94x | -89.41x | -43.11x | -36.63x | -63.57x |
| Total Equity | 964.9M▲ 0% | 1.09B▲ 12.9% | 1.09B▲ 0.0% | 881M▼ 19.1% | 967.8M▲ 9.9% | 885.8M▼ 8.5% | 783.2M▼ 11.6% | 701.1M▼ 10.5% | 368M▼ 47.5% | 337.4M▲ 0% |
| Equity Growth % | 24.05% | 12.85% | 0% | -19.09% | 9.85% | -8.47% | -11.58% | -10.48% | -47.51% | -196.29% |
| Book Value per Share | 13.40 | 14.33 | 14.66 | 11.78 | 12.41 | 10.99 | 9.46 | 7.74 | 3.94 | 3.60 |
| Total Shareholders' Equity | 964.9M | 1.09B | 1.09B | 881M | 967.8M | 885.8M | 783.2M | 701.1M | 368M | 337.4M |
| Common Stock | 700K | 700K | 700K | 800K | 800K | 800K | 900K | 900K | 900K | 900K |
| Retained Earnings | 52.8M | 25.6M | 25.6M | -227M | -254.2M | -366.2M | -629.5M | -756.8M | -1.12B | -1.16B |
| Treasury Stock | - | - | - | - | - | - | 0 | 0 | 0 | 0 |
| Accumulated OCI | -4M | -5.4M | -5.4M | -2.3M | -5.1M | -8.9M | -3.7M | -800K | 800K | 700K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
MYGN Cash Flow Statement
Myriad Genetics, Inc. (MYGN) cash flow — operating, investing & free cash flow history
| Line item | Jun'18 | Jun'19 | Jun'20 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | 115.9M | 83.7M | 60.7M | -26.9M | 18.6M | -106.3M | -110.9M | -8.7M | 1.8M | 1.8M |
| Operating CF Margin % | 15% | 9.83% | 9.51% | -4.83% | 2.69% | -15.67% | -14.72% | -1.04% | 0.22% | - |
| Operating CF Growth % | 9.13% | -27.78% | -27.48% | -144.32% | 169.14% | -671.51% | -4.33% | 92.16% | 120.69% | 2355.5% |
| Net Income | 133.3M | 4.6M | -199.5M | -223.7M | -27.2M | -112M | -263.3M | -127.3M | 0 | -399.9M |
| Depreciation & Amortization | 54.4M | 73M | 72M | 71.4M | 62.8M | 52.7M | 61.9M | 61.2M | 0 | 39.2M |
| Stock-Based Compensation | 27.1M | 33.5M | 25.2M | 24.3M | 36.3M | 38.1M | 40.7M | 49.8M | 0 | 29.4M |
| Deferred Taxes | -23.8M | 13.1M | -54.1M | -54.5M | -34.7M | -31.9M | -600K | -300K | 0 | -200K |
| Other Non-Cash Items | -83.6M | -1.1M | 99.2M | 70.9M | -139.4M | 30.3M | 23.4M | 62.3M | 21.1M | 333.2M |
| Working Capital Changes | 8.5M | -39.4M | 117.9M | 30.2M | 120.8M | -83.5M | 27M | -54.4M | -19.3M | -7.2M |
| Change in Receivables | -8M | -18.2M | 64M | 28.9M | -8.8M | 7.7M | 3.8M | -8.7M | 6.2M | 5.4M |
| Change in Inventory | 7.9M | 8M | 1.6M | 1.3M | 1.6M | -2.9M | -1.8M | -6.2M | -3.2M | -2.3M |
| Change in Payables | 4M | 1.1M | -10.7M | 0 | 9.2M | -3.5M | -3.7M | 4.7M | -1.4M | -1.4M |
| Cash from Investing | -11.6M | -286.4M | 19.3M | 61.6M | 274.4M | -77.5M | 31.9M | -11.9M | -27.4M | -25.6M |
| Capital Expenditures | -8.4M | -8.6M | -10.2M | -13.2M | -18M | -45.3M | -73.3M | -29.7M | -27.4M | -19.1M |
| CapEx % of Revenue | 1.09% | 1.01% | 1.6% | 2.37% | 2.61% | 6.68% | 9.73% | 3.55% | 3.32% | - |
| Acquisitions | 0 | -278.5M | 21.3M | 0 | 379.1M | -57.2M | 0 | 8.8M | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 74.8M | 0 | 0 | 0 | 0 | 0 | -6.5M |
| Cash from Financing | -95M | 182.3M | -10M | -1M | -150.6M | -8M | 152.9M | -7.4M | 64.2M | 47.6M |
| Debt Issued (Net) | -90M | 225M | -8.6M | - | -226.4M | - | 39.8M | 100K | 75.9M | 64.6M |
| Equity Issued (Net) | - | -50M | - | - | - | - | 117.6M | 0 | 3.3M | 3.3M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | -50M | 0 | -3.9M | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -5M | 7.3M | -1.4M | 11.5M | 75.8M | -8M | -4.5M | -7.5M | -15M | -20.3M |
| Net Change in Cash | 8.5M▲ 0% | -17.7M▼ 308.2% | 70.5M▲ 498.3% | 70.5M▲ 0.0% | 141.8M▲ 101.1% | -192.4M▼ 235.7% | 74.5M▲ 138.7% | -29M▼ 138.9% | 39.4M▲ 235.9% | 25M▲ 0% |
| Free Cash Flow | 107.5M▲ 0% | 75.1M▼ 30.1% | 50.5M▼ 32.8% | -40.1M▼ 179.4% | 600K▲ 101.5% | -151.6M▼ 25366.7% | -184.2M▼ 21.5% | -38.4M▲ 79.2% | -13.8M▲ 64.1% | -20.8M▲ 0% |
| FCF Margin % | 13.91% | 8.82% | 7.91% | -7.2% | 0.09% | -22.35% | -24.46% | -4.58% | -1.67% | -2.51% |
| FCF Growth % | 7.39% | -30.14% | -32.76% | -179.41% | 101.5% | -25366.67% | -21.5% | 79.15% | 64.06% | 41.9% |
| FCF per Share | 1.49 | 0.99 | 0.68 | -0.54 | 0.01 | -1.88 | -2.22 | -0.42 | -0.15 | -0.15 |
| FCF Conversion (FCF/Net Income) | 0.88x | 18.20x | -0.30x | 0.12x | -0.68x | 0.95x | 0.42x | 0.07x | -0.00x | 0.05x |
| Interest Paid | 3M | 11.6M | 9.5M | - | 4.4M | - | 1.4M | 1.9M | 0 | 1.2M |
| Taxes Paid | 11.7M | 6.5M | 1M | - | 4.6M | 1.8M | 1.9M | 2.7M | 0 | 0 |
MYGN Key Ratios
Myriad Genetics, Inc. (MYGN) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | 15.03% | 0.45% | -18.32% | -22.71% | -2.94% | -12.08% | -31.55% | -17.15% | -68.45% | -109.09% |
| Return on Invested Capital (ROIC) | 10.87% | 0.54% | -14.14% | -12.8% | -15.41% | -11.88% | -21.73% | -12.01% | -8.71% | -8.71% |
| Gross Margin | 77.06% | 76.38% | 70.86% | 68.01% | 71.39% | 70.22% | 68.64% | 69.89% | 69.93% | 69.96% |
| Net Margin | 16.96% | 0.54% | -31.24% | -40.16% | -3.94% | -16.51% | -34.96% | -15.2% | -44.38% | -48.24% |
| Debt / Equity | 0.01x | 0.21x | 0.21x | 0.33x | 0.10x | 0.16x | 0.19x | 0.20x | 0.57x | 0.57x |
| Interest Coverage | 37.09x | 1.00x | -19.68x | - | -7.65x | -42.94x | -89.41x | -43.11x | -36.63x | -63.57x |
| FCF Conversion | 0.88x | 18.20x | -0.30x | 0.12x | -0.68x | 0.95x | 0.42x | 0.07x | -0.00x | 0.05x |
| Revenue Growth | 0.16% | 10.16% | -24.97% | -12.78% | 23.99% | -1.77% | 11.03% | 11.21% | -1.56% | -0.28% |
MYGN SEC Filings & Documents
Myriad Genetics, Inc. (MYGN) SEC filings — annual & quarterly reports (10-K, 10-Q)
MYGN Frequently Asked Questions
Myriad Genetics, Inc. (MYGN) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Myriad Genetics, Inc. (MYGN) reported $829.0M in revenue for fiscal year 2025. This represents a 5354% increase from $15.2M in 1996.
Myriad Genetics, Inc. (MYGN) saw revenue decline by 1.6% over the past year.
Myriad Genetics, Inc. (MYGN) reported a net loss of $399.9M for fiscal year 2025.
Dividend & Returns
Myriad Genetics, Inc. (MYGN) has a return on equity (ROE) of -68.5%. Negative ROE indicates the company is unprofitable.
Myriad Genetics, Inc. (MYGN) had negative free cash flow of $20.8M in fiscal year 2025, likely due to heavy capital investments.
Explore More MYGN
Myriad Genetics, Inc. (MYGN) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates